John is a 45-year-old male recently diagnosed with active psoriatic arthritis (PsA). He is biologic-naïve and currently on methotrexate 15 mg weekly but reports persistent joint pain and fatigue affecting his daily activities. He is interested in starting a biologic therapy to improve his symptoms and quality of life. He has no known drug allergies and works full-time as a software engineer.

Question: Based on the 1-year results from phase III studies, what benefit can John most likely expect from initiating bimekizumab 160 mg subcutaneously every 4 weeks in addition to methotrexate?

Maria is a 52-year-old female with active psoriatic arthritis who has had an inadequate response to tumor necrosis factor inhibitors (TNFi). She reports ongoing joint pain, fatigue, and difficulty maintaining work productivity as a school teacher. Her current medications include low-dose prednisone 5 mg daily and NSAIDs as needed. She is considering switching to bimekizumab therapy.

Question: What patient-reported outcome improvements can Maria expect after 1 year of bimekizumab treatment based on clinical trial data for TNFi-IR patients?

David is a 38-year-old male with active psoriatic arthritis who started bimekizumab 160 mg SC every 4 weeks six months ago after failing NSAIDs and conventional DMARDs. He reports improved joint pain but is concerned about how this treatment might affect his ability to maintain work attendance and performance as a construction manager.

Question: According to 1-year clinical trial data, how does bimekizumab treatment impact work productivity and activity impairment in patients with active psoriatic arthritis?